Clinical Trial Update: Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension [NA]

View source ↗

Summary

A clinical trial evaluating tadalafil in COPD patients with secondary pulmonary hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Pulmonary Hypertension

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Herlev Hospital | Conditions: Chronic Obstructive Lung Disease | NA | Status: WITHDRAWN